Primary research
Original GLP-1 research + data reports
Primary-data investigations and CC-BY-licensed datasets. Every report cites methodology + source links per row + a public refresh cadence. Other journalists are encouraged to cite — attribution to Glpverdict is the only requirement.
2026-07-17 · Refreshed on secondary SELECT analyses or new CV outcomes trial
SELECT trial deep-dive — does Wegovy actually reduce heart attack risk?
Landmark NEJM 2023 trial (Lincoff, n=17,604, 3.3 years). 20% MACE reduction on semaglutide 2.4 mg vs placebo in overweight/obese adults with CV disease. Full endpoint breakdown + weight-independent mechanism analysis + FDA March 2024 label expansion.
Read the report
2026-07-17 · Refreshed on any new large-cohort MTC data or FDA labeling change
GLP-1 and thyroid cancer (MTC): the honest evidence read
The FDA black-box is based on rat carcinogenicity studies. Human data through mid-2026 (SELECT, LEADER, Danish nationwide) does not show an MTC signal. What we know, what we do not, and who should still avoid the drug (MEN2, MTC family history).
Read the report
2026-07-17 · Refreshed on any new low-dose GLP-1 trial or FDA label change
GLP-1 microdosing: 2026 evidence review
Off-label and largely unstudied. What STEP-1, SURMOUNT-1, the FDA labels, and AACE 2024 guidelines actually say about doses below the approved obesity range. No hype, no anecdotal generalization.
Read the report
2026-07-17 · Quarterly refresh + on KFF update
State Medicaid GLP-1 coverage 2026: 51-jurisdiction teardown
12 states cover weight-loss GLP-1s under fee-for-service Medicaid. 4 dropped coverage after October 2025. Full state-by-state buckets with KFF + state PDL sourcing.
Read the report
2026-07-17 · Quarterly refresh + on national inclusion/exclusion event
PBM formulary GLP-1 teardown 2026 — CVS, Express Scripts, OptumRx, MedImpact, Prime
Head-to-head PBM analysis for Wegovy + Zepbound access. OptumRx dropped Zepbound Premium formulary July 2025 — precedent-setting national exclusion. Full PA + step-therapy stance per PBM.
Read the report
2026-07-17 · Refreshed on FDA shortage listing/de-listing or MDL milestone
GLP-1 shortage retrospective 2022-2026 — timeline, compounding wind-down, MDL-3094
Full FDA shortage-cycle retrospective. Semaglutide + tirzepatide declaration → resolution → 503B wind-down. Includes OFA v. FDA litigation and MDL-3094 consolidation in E.D. Pa.
Read the report
2026-07-17 · Refreshed on new peer-reviewed replication cohort or label change
Semaglutide + NAION 2024-2026 — evidence review + FAERS surveillance
Full evidence stack on the JAMA Ophthalmology 2024 signal, Danish replication, FAERS Reporting Odds Ratio, and label status. Notoriety bias explained. FDA has not amended label as of mid-2026.
Read the report
2026-07-11 · Refreshed on new peer-reviewed trial
Semaglutide and alcohol use disorder: what the 2022-2026 evidence actually shows
Five-study evidence review — Danish nationwide cohort, US EHR cohort, human lab RCT, animal work. Direction is reproducibly reduced drinking; effect size is modest; no phase-3 RCT reports yet.
Read the report
2026-06-01 · Quarterly refresh
The 2026 GLP-1 cash price spread: 24 cash-pay sources compared
Primary-data investigation of cash-pay prices across compounded 503A, brand-name telehealth, manufacturer-direct, and pharmacy-coupon channels. 9× spread.
Read the report